Cleveland HeartLab (“CHL”) is a next generation diagnostics company and reference laboratory focused on novel molecular biomarker technologies and the creation of proprietary diagnostic tests that address critical unmet needs in patient care. The Company’s biomarker technologies were spun out of The Cleveland Clinic Foundation (“CCF”). CHL was formed in 2009 to develop and rapidly commercialize its potential diagnostic technologies with applications in cardiovascular and inflammatory indications. The Company has a significant pipeline of tests that are protected or protectable and target large, under addressed markets. In addition, an agreement with the CCF provides the Company with special rights to all intellectual property developed at CCF in the areas of cardiovascular and inflammatory biomarkers.
The Company is based in Cleveland, Ohio and has over 100 employees, including 3 PhD’s and 2 MD’s. Led by its CEO, Jake Orville, the Company has experienced management with significant expertise in biomarker technology and product development, diagnostic test marketing, reference laboratory, and disease management.